Data fraud allegedly delayed FDA nod for Pfizer-BMS drug Eliquis

Data errors and alleged fraud at clinical trial sites in China held up approval of Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) clot-fighting drug Eliquis, according to media reports. The allegations could raise more questions about the integrity of drug research in China. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.